An Exploratory, Pilot, Single-site Study to Evaluate the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Diagnosis of mild to moderate OAG, mild to moderate NTG, or stable NPDR in at least one eye.
• Corrected visual acuity in each eye +1.0 logMAR or better by early treatment diabetic retinopathy study (ETDRS) in each eye (equivalent to 20/200).
• Able and willing to give signed informed consent and follow study instructions.
Locations
United States
California
Stanford University, Dept. of Ophthalmology
RECRUITING
Palo Alto
Contact Information
Primary
Lisa Brandano
lbrandano@qlaris.bio
978-930-2103
Time Frame
Start Date: 2026-02-20
Estimated Completion Date: 2026-06
Participants
Target number of participants: 14
Treatments
Experimental: QLS-111 Ophthalmic Solution, 2 concentrations (0.015% and 0.075%, concurrent) dosed BID for 7 days
QLS-111 Ophthalmic Solution, 2 concentrations (0.015% and 0.075%) dosed BID for 7 days (taken 12-hour intervals) OU.
Related Therapeutic Areas
Sponsors
Leads: Qlaris Bio, Inc.